Journal Article

Extended-spectrum β-lactamases in non-typhoidal <i>Salmonella</i> spp. isolated in the UK are now a reality: why the late arrival?

Catherine Yates and Sebastian Amyes

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 56, issue 2, pages 262-264
Published in print August 2005 | ISSN: 0305-7453
Published online July 2005 | e-ISSN: 1460-2091 | DOI:
Extended-spectrum β-lactamases in non-typhoidal Salmonella spp. isolated in the UK are now a reality: why the late arrival?

Show Summary Details


In February 2004, we reported the first recognition of the presence of an extended-spectrum β-lactamase (ESBL) in non-typhoidal Salmonella spp. in the UK; the β-lactamase was TEM-52. Six months later, an SHV-derived ESBL (SHV-12) was detected in a salmonella strain isolated in York and 6 months after that we have just identified CTX-M-type β-lactamases in Scottish isolates of Salmonella enterica subsp. enterica serovar Typhimurium and Salmonella Virchow (unpublished results). A very recent retrospective study of UK isolates suggests that they may have been in the population for some years but have gone undetected. Even so, compared with reports of ESBLs in Salmonella spp. elsewhere, these results are suggestive of a delayed emergence of the ESBL phenotype in non-typhoidal Salmonella spp. in the UK. Should the British congratulate themselves on warding off the emergence of these important resistance mechanisms in Salmonella spp., or is the sudden revelation of three of the major ESBL types a cause for concern?

Keywords: ESBLs; emergence; TEM; CTX-M

Journal Article.  1712 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.